Comparative Pharmacology
Head-to-head clinical analysis: APREPITANT versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APREPITANT versus ZUPLENZ.
APREPITANT vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective high-affinity antagonist of the human substance P/neurokinin 1 (NK1) receptor, inhibiting emesis by blocking the binding of substance P in the central nervous system.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
125 mg orally once on day 1, then 80 mg orally once on days 2 and 3 of a 3-day chemotherapy regimen, given 1 hour before chemotherapy. Alternatively, a single 165 mg oral dose for prevention of postoperative nausea and vomiting.
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
Clinical Note
moderateAprepitant + Torasemide
"The metabolism of Torasemide can be increased when combined with Aprepitant."
Clinical Note
moderateAprepitant + Lornoxicam
"The metabolism of Lornoxicam can be increased when combined with Aprepitant."
Clinical Note
moderateAprepitant + Aceclofenac
"The metabolism of Aceclofenac can be increased when combined with Aprepitant."
Clinical Note
moderateAprepitant + Zaltoprofen
Terminal elimination half-life is approximately 9 to 13 hours in adults, allowing once-daily dosing. In pediatric patients, half-life may be shorter (about 5-6 hours).
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Aprepitant is eliminated primarily by metabolism; less than 5% is excreted unchanged in urine or feces. Approximately 50% of a dose is recovered in feces (mostly metabolites) and 10% in urine.
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category C
Category C
Antiemetic
Antiemetic
"The metabolism of Zaltoprofen can be increased when combined with Aprepitant."